Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss

Recruiting now · Phase 1/Phase 2

Conditions studied: GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A

In brief

Skylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being developed to treat children who have hearing loss due to changes in the GJB2 gene (also referred to as Connexin 26). The SKY-CAT is a device that delivers the gene therapy. The purpose of this study is to: Learn about the safety and tolerability (does not cause ongoing discomfort) of SKY-GJB2 Evaluate the efficacy of SKY-GJB2 (how well is works)

Key facts

Study ID
NCT07627971
Run by
Skylark Bio Inc.
People needed
10
Starts
2026-05-28
Expected to finish
2028-06-01
Last updated by the study team
2026-07-15

Who can join

Age: 1 and older, up to 7. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.